Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.19 | -0.21% | 90.61 | 92,767 | 08:47:45 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 90.59 | 90.60 | 90.94 | 90.40 | 90.44 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Health & Allied Services,nec | 43.07B | 5.4B | 4.3109 | 21.07 | 113.74B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:47:20 | 19 | 90.61 | EUR |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/11/2024 | 13:11 | UKREG | Sanofi: Informations relatives au nombre de droits de vote et d'actions -.. |
| 20/11/2024 | 13:11 | UKREG | Sanofi: Information concerning the total number of voting rights and shares.. |
| 15/11/2024 | 06:00 | UKREG | Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le.. |
| 15/11/2024 | 06:00 | UKREG | Press Release: Dupixent sBLA accepted for FDA review for the treatment of.. |
| 14/11/2024 | 16:42 | UKREG | Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans.. |
| 14/11/2024 | 16:42 | UKREG | Press Release: Sarclisa recommended for EU approval by the CHMP to treat.. |
| 06/11/2024 | 06:00 | UKREG | Press Release: Dupixent approved in the EU as the first and only medicine.. |
| 06/11/2024 | 06:00 | UKREG | Communiqué de presse : Dupixent, premier et seul médicament approuvé dans.. |
| 25/10/2024 | 05:30 | UKREG | Communiqué de presse : T3 2024 : Croissance des ventes de 15,7% soutenue.. |
| 25/10/2024 | 05:30 | UKREG | Press Release: Sanofi Q3: 15.7% sales growth boosted by.. |
Sanofi (SAN) Share Charts1 Year Sanofi Chart |
|
1 Month Sanofi Chart |
Intraday Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
